IMR Press / EJGO / Volume 8 / Issue 2 / pii/1987017

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Antiemetic combination for pac (cisplatin -adriamycin - cyclophosphamide) chemotherapy-induced emesis in ovarian cancer

Show Less
1 Servicio de Oncologia Medica - Hospital Clinico San Carlos, Madrid, Spain
Eur. J. Gynaecol. Oncol. 1987, 8(2), 98–104;
Published: 10 April 1987

Twenty-six patients suffering from disseminated epithelial ovarian cancer (FIGO stages III and IV) under treatment with Cisplatin (80-100 mg/m2 in 8 hours) in combination on the- same day with Cyclophosphamide (500 mg/m2 IV) and Adriamycin (50 mg/m2,a severely eme­togenic regimen, entered a randomized, double-blind, cross-over trial. comparing the antiemetic activity of high-dose IV Metoclopramide (1 mg/kg/dose × 5 doses) with that of a combination of Metodopramide (same schedule) plus Nortriptyline (50 mg PO × 2 doses) plus Thiethylperazine (10 mg IV × 3 doses). The antiemetic combination was designed in an attempt to act simulta­neously on gastrointestinal motility and neuroreceptors at the central emetic pathways (dopamine D-2, histamine H-1 and muscarinic cholinergic). This combination significantly reduced the emesis due to chemotherapy when compared with Metoclopramide alone and was also preferred by a signi­ficant number of patients after passing through both the antiemetic arms being compared. 

Chemotherapy - induced emesis
Combination antiemetics
Back to top